RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma

BACKGROUND: Neoadjuvant chemotherapy – often using docetaxel in various combinatorial regimens – is a standard treatment choice for advanced oesophageal squamous cell carcinoma (ESCC) in Japan. However, no useful markers exist that predict docetaxel’s effects on ESCC. Ribophorin II (RPN2) silencing,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kurashige, J, Watanabe, M, Iwatsuki, M, Kinoshita, K, Saito, S, Nagai, Y, Ishimoto, T, Baba, Y, Mimori, K, Baba, H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494434/
https://ncbi.nlm.nih.gov/pubmed/22955852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.396
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados